Compare FORTY & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FORTY | ADMA |
|---|---|---|
| Founded | 1985 | 2004 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 1998 | 2012 |
| Metric | FORTY | ADMA |
|---|---|---|
| Price | $106.50 | $8.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $25.67 |
| AVG Volume (30 Days) | 414.0 | ★ 3.3M |
| Earning Date | 05-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | ★ $42,219,783.00 |
| Revenue This Year | N/A | $27.46 |
| Revenue Next Year | N/A | $22.11 |
| P/E Ratio | ★ $36.65 | $45.89 |
| Revenue Growth | N/A | ★ 43.85 |
| 52 Week Low | $106.50 | $7.21 |
| 52 Week High | $190.56 | $20.46 |
| Indicator | FORTY | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 33.61 | 52.30 |
| Support Level | $101.21 | $7.38 |
| Resistance Level | $136.43 | $8.90 |
| Average True Range (ATR) | 1.43 | 0.33 |
| MACD | -2.88 | 0.12 |
| Stochastic Oscillator | 0.00 | 67.24 |
Formula Systems (1985) Ltd is an information technology company that is principally engaged through its directly and indirectly held investees in providing software consulting services, selling and marketing computer-based business solutions and hardware products from a wide range of domestic and international manufacturers, as well as developing proprietary software solutions. It delivers solutions in Israel and in numerous countries to customers with complex IT services needs. It designs and implements IT solutions and software systems that improve the productivity of customers' existing IT assets, enable them to effectively manage their operations and reduce their business risks in the face of changing business environments.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.